Edwards Lifesciences Corp (EW)vsPulmonx Corp (LUNG)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
LUNG
Pulmonx Corp
$1.85
0.00%
HEALTHCARE · Cap: $97.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 7348% more annual revenue ($6.51B vs $87.44M). EW leads profitability with a 15.4% profit margin vs -55.0%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
LUNG
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Intrinsic value data unavailable for LUNG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : LUNG
The strongest argument for LUNG centers on Price/Book.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : LUNG
The primary concerns for LUNG are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
EW profiles as a mature stock while LUNG is a turnaround play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 28/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Pulmonx Corp
HEALTHCARE · MEDICAL DEVICES · USA
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?